PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Holdings Boosted by BML Capital Management LLC

Key Points

• BML Capital Management LLC increased its stake in PMV Pharmaceuticals by 8.1% in Q1, owning approximately 3.1% of the company after buying an additional 280,928 shares.
• CEO David Henry Mack sold 58,411 shares on July 1st, decreasing his ownership by 9.82%, while insiders have collectively sold 114,627 shares worth $121,505 in the last quarter.
• PMV Pharmaceuticals reported a loss of ($0.34) earnings per share for Q1, surpassing analyst expectations of ($0.37).

BML Capital Management LLC raised its stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 8.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,747,612 shares of the company's stock after acquiring an additional 280,928 shares during the quarter. PMV Pharmaceuticals makes up 3.1% of BML Capital Management LLC's portfolio, making the stock its 11th biggest holding. BML Capital Management LLC owned approximately 7.21% of PMV Pharmaceuticals worth $4,085,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in PMVP. JPMorgan Chase & Co. grew its position in PMV Pharmaceuticals by 2,282.8% during the fourth quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock valued at $37,000 after acquiring an additional 23,559 shares during the period. Velan Capital Investment Management LP purchased a new stake in PMV Pharmaceuticals during the fourth quarter valued at about $53,000. Squarepoint Ops LLC grew its position in PMV Pharmaceuticals by 68.7% during the fourth quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock valued at $110,000 after acquiring an additional 29,722 shares during the period. Northern Trust Corp grew its position in PMV Pharmaceuticals by 23.2% during the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company's stock valued at $162,000 after acquiring an additional 20,190 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in PMV Pharmaceuticals by 44.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock valued at $305,000 after acquiring an additional 62,200 shares during the period. 90.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Deepika Jalota sold 33,065 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total value of $35,048.90. Following the completion of the sale, the insider owned 89,959 shares of the company's stock, valued at $95,356.54. This represents a 26.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David Henry Mack sold 58,411 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total value of $61,915.66. Following the completion of the sale, the chief executive officer directly owned 536,133 shares of the company's stock, valued at $568,300.98. The trade was a 9.82% decrease in their position. The disclosure for this sale can be found here. Insiders sold 114,627 shares of company stock valued at $121,505 in the last ninety days. Company insiders own 7.57% of the company's stock.

PMV Pharmaceuticals Price Performance

PMVP stock traded down $0.09 during trading on Tuesday, reaching $1.42. 175,493 shares of the stock traded hands, compared to its average volume of 204,967. The business's 50 day moving average price is $1.12 and its 200-day moving average price is $1.17. PMV Pharmaceuticals, Inc. has a 52-week low of $0.81 and a 52-week high of $1.82. The firm has a market capitalization of $73.83 million, a PE ratio of -1.20 and a beta of 1.49.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.03. On average, equities research analysts predict that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.